                         SEQUENCE LISTING

<110>  Palatin Technologies, Inc.
       Yang, Wei
       Shi, Yi-Qun
 
<120>  Melanocortin-1 Receptor-Specific Cyclic Peptides

<130>  1011-137

<150>  61/263,490
<151>  2009-11-23

<160>  69    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Homo sapiens

<400>  1

His Phe Arg Trp 
1               


<210>  2
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic analog of SEQ ID NO:2


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (13)..(13)
<223>  AMIDATION

<400>  2

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 
1               5                   10              


<210>  3
<211>  13
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-Phe

<220>
<221>  MOD_RES
<222>  (13)..(13)
<223>  AMIDATION

<400>  3

Ser Tyr Ser Xaa Glu His Xaa Arg Trp Gly Lys Pro Val 
1               5                   10              


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  4

Xaa Glu His Xaa Arg Lys Trp 
1               5           


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  5

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dap

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  6

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dap

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  7

Xaa Asp His Xaa Arg Xaa Trp 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge Through disulfide

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  8

Xaa Cys His Xaa Arg Cys Trp 
1               5           


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Orn

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  9

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  10

Xaa Glu His Xaa Arg Xaa Xaa 
1               5           


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  11

Xaa Glu His Phe Arg Xaa Trp 
1               5           


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-Nal 1

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  12

Xaa Glu His Xaa Arg Xaa Xaa 
1               5           


<210>  13
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Nal 2

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  13

Xaa Glu His Xaa Arg Xaa Xaa 
1               5           


<210>  14
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  D-Nal 2

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  14

Xaa Glu His Xaa Arg Xaa Xaa 
1               5           


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  15

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  16
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  16

Phe Glu His Xaa Arg Xaa Trp 
1               5           


<210>  17
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Succinic acid

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  17

Xaa His Phe Arg Xaa Trp 
1               5       


<210>  18
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal CH3-(CH2)2-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  18

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal CH3-(CH2)3-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  19

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  20
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal CH3-(CH2)4-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  20

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  21
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal CH3-(CH2)5-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  21

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  22
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal cyclo-propanoyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  22

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  23
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal cyclo-hexanoyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  23

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  24
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal cycopentyl acetyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  24

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  25
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal cyclohexyl acetyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  25

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  26
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal phenyl acetyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  26

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  27
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-Terminal phenyl propanoyl-

<220>
<221>  MISC_FEATURE
<222>  (1)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  27

Glu His Xaa Arg Xaa Trp 
1               5       


<210>  28
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(7)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  28

Xaa Glu His Xaa Arg Xaa Ala 
1               5           


<210>  29
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dap

<400>  29

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  30
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge through -C(=O)-(CH2)2-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  30

Xaa Xaa His Xaa Arg Xaa Trp 
1               5           


<210>  31
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Dap

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge Through -C(=O)-(CH2)2-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dap

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  31

Xaa Xaa His Xaa Arg Xaa Trp 
1               5           


<210>  32
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge Through -C(=O)-(CH2)2-C(C=O)-

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dap

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  32

Xaa Xaa His Xaa Arg Xaa Trp 
1               5           


<210>  33
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Nal 1

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  33

Xaa Glu His Xaa Arg Xaa Xaa 
1               5           


<210>  34
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<400>  34

Xaa Glu His Xaa Arg Xaa Trp 
1               5           


<210>  35
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  35

Xaa Glu His Xaa Arg Xaa 
1               5       


<210>  36
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  36

Xaa Glu His Xaa Ala Xaa 
1               5       


<210>  37
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  37

Xaa Glu His Xaa Gly Xaa Trp 
1               5           


<210>  38
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  38

Xaa Glu His Xaa Ala Xaa Trp 
1               5           


<210>  39
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  39

Xaa Glu Ala Xaa Arg Xaa Trp 
1               5           


<210>  40
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  40

Xaa Glu Arg Xaa Arg Xaa Trp 
1               5           


<210>  41
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Cit

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  41

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  42
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  42

Xaa Glu His Xaa Arg Xaa Lys 
1               5           


<210>  43
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  43

Xaa Glu Lys Xaa Arg Xaa Trp 
1               5           


<210>  44
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  44

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  45
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  45

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  46
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Dap

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge Through -C(=O)-(CH2)2-C(=O)-

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  46

Xaa Xaa His Xaa Arg Xaa Trp 
1               5           


<210>  47
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  47

Xaa Glu His Xaa Arg Xaa 
1               5       


<210>  48
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  48

Xaa Glu His Xaa Ala Xaa 
1               5       


<210>  49
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(5)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  AMIDATION

<400>  49

Xaa Glu His Xaa Xaa 
1               5   


<210>  50
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  50

Xaa Glu His Xaa Gly Xaa Trp 
1               5           


<210>  51
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  51

Xaa Glu His Xaa Ala Xaa Trp 
1               5           


<210>  52
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  52

Xaa Glu Ala Xaa Arg Xaa Trp 
1               5           


<210>  53
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  53

Xaa Glu Arg Xaa Arg Xaa Trp 
1               5           


<210>  54
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Cit

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  54

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  55
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  55

Xaa Glu His Xaa Arg Xaa Lys 
1               5           


<210>  56
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  56

Xaa Glu Lys Xaa Arg Xaa Trp 
1               5           


<210>  57
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Dab

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  57

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  58
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  58

Xaa Glu Xaa Xaa Arg Xaa Trp 
1               5           


<210>  59
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  59

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  60
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(2-Cl)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  60

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  61
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(3-Cl)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  61

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  62
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(4-Cl)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  62

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  63
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(2-F)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  63

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  64
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(4-F)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  64

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  65
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(3,4-F)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  65

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  66
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(4-Me)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  66

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  67
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Orn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe(4-OMe)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  67

Xaa Glu Xaa Xaa Arg Xaa 
1               5       


<210>  68
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  68

Xaa Glu Pro Xaa Arg Xaa 
1               5       


<210>  69
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic melanocortin-1 receptor-specific peptide of invention


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  ACETYLATION

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Nle

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  Cyclic Bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Phe

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Dab

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  69

Xaa Glu Pro Xaa Arg Xaa Trp 
1               5           


